US5686292A
(en)
*
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US6214344B1
(en)
*
|
1995-06-02 |
2001-04-10 |
Genetech, Inc. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
WO1997012629A1
(en)
*
|
1995-10-05 |
1997-04-10 |
Genentech, Inc. |
Improved angiogenesis using hepatocyte growth factor
|
IL127558A0
(en)
*
|
1996-07-03 |
1999-10-28 |
Genentech Inc |
Hepatocyte growth factor receptor agonists and uses thereof
|
AU2333999A
(en)
*
|
1998-01-23 |
1999-08-09 |
Prolifaron, Inc. |
Methods and compositions for the identification of growth factor mimetics, growth factors and inhibitors
|
US20020136721A1
(en)
*
|
1998-02-17 |
2002-09-26 |
Schwall Ralph H. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
EP1074264B1
(en)
*
|
1998-04-28 |
2008-09-17 |
Toshikazu Nakamura |
Neovascularization inhibitors
|
AU770920C
(en)
*
|
1999-03-23 |
2004-10-07 |
Georgetown University |
Phenylalanine derivatives
|
US7226991B1
(en)
*
|
1999-03-23 |
2007-06-05 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Phenylalanine derivatives
|
JP2003533968A
(ja)
*
|
1999-09-03 |
2003-11-18 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
免疫グロブリンスーパーファミリーポリヌクレオチド、ポリペプチド、および抗体
|
WO2001028577A2
(en)
|
1999-10-22 |
2001-04-26 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain
|
US7871981B2
(en)
*
|
1999-10-22 |
2011-01-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibition of cell motility, angiogenesis, and metastasis
|
WO2002016407A2
(en)
*
|
2000-08-22 |
2002-02-28 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Sh2 domain binding inhibitors
|
US7425537B2
(en)
*
|
2000-08-22 |
2008-09-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SH2 domain binding inhibitors
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US9249229B2
(en)
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
JP4280803B2
(ja)
|
2000-12-08 |
2009-06-17 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
慢性リンパ性白血病細胞株および抗体を産生するためのその使用
|
US20020151508A1
(en)
*
|
2001-02-09 |
2002-10-17 |
Schering Corporation |
Methods for treating proliferative diseases
|
US20030118585A1
(en)
*
|
2001-10-17 |
2003-06-26 |
Agy Therapeutics |
Use of protein biomolecular targets in the treatment and visualization of brain tumors
|
JP2003238592A
(ja)
*
|
2001-12-13 |
2003-08-27 |
Japan Tobacco Inc |
組織及び血管の再生のための医薬及びその方法
|
US7261876B2
(en)
|
2002-03-01 |
2007-08-28 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
US20050100963A1
(en)
|
2002-03-01 |
2005-05-12 |
Dyax Corporation |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
US7794693B2
(en)
*
|
2002-03-01 |
2010-09-14 |
Bracco International B.V. |
Targeting vector-phospholipid conjugates
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
US8623822B2
(en)
|
2002-03-01 |
2014-01-07 |
Bracco Suisse Sa |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
AT413487B
(de)
*
|
2002-08-12 |
2006-03-15 |
Igeneon Krebs Immuntherapie |
Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
|
PT1539798E
(pt)
*
|
2002-09-06 |
2011-02-23 |
Genentech Inc |
Processo para extracção de proteínas
|
US20040138104A1
(en)
*
|
2003-01-14 |
2004-07-15 |
The Government Of The United States Of America Represented By The Secretary, |
Peptides
|
WO2004072117A2
(en)
*
|
2003-02-13 |
2004-08-26 |
Pharmacia Corporation |
Antibodies to c-met for the treatment of cancers
|
CA2517939C
(en)
*
|
2003-03-03 |
2015-11-24 |
Dyax Corp. |
Peptides that specifically bind hgf receptor (cmet) and uses thereof
|
US20040208876A1
(en)
*
|
2003-04-18 |
2004-10-21 |
Kim Kyung Jin |
Monoclonal antibodies to hepatocyte growth factor
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
ITMI20031127A1
(it)
*
|
2003-06-05 |
2004-12-06 |
Uni Degli Studi Del Piemont E Orientale Am |
Anticorpi anti-hgf-r e loro uso
|
EP2093570A1
(en)
*
|
2003-06-06 |
2009-08-26 |
Genentech, Inc. |
Modulating the interaction between HGF beta chain and c-met
|
RS53476B
(en)
*
|
2003-07-18 |
2014-12-31 |
Amgen Fremont Inc. |
Hepatocyte Growth Factor Binders
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
US20050119163A1
(en)
|
2003-09-18 |
2005-06-02 |
The Government Of The United States Of America, As Represented By The Secretary, |
SH2 domain binding inhibitors
|
JP2008507252A
(ja)
*
|
2003-12-11 |
2008-03-13 |
ジェネンテック・インコーポレーテッド |
C−met二量体化及び活性化を阻害するための方法と組成物
|
ZA200604864B
(en)
*
|
2003-12-19 |
2007-10-31 |
Genentech Inc |
Monovalent antibody fragments useful as therapeutics
|
EP1720574A4
(en)
*
|
2004-02-23 |
2009-09-09 |
Sugen Inc |
METHOD OF TREATING ABNORMAL CELL GROWTH USING C-MET AND M-TOR INHIBITORS
|
WO2005108424A1
(en)
*
|
2004-05-06 |
2005-11-17 |
Genentech, Inc. |
Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
|
US20060003931A1
(en)
*
|
2004-05-06 |
2006-01-05 |
Genentech, Inc. |
Crystal structure of the hepatocyte growth factor and methods of use
|
CN102942631B
(zh)
*
|
2004-08-05 |
2015-03-25 |
健泰科生物技术公司 |
人源化抗c-met拮抗剂
|
NZ556788A
(en)
|
2005-01-05 |
2011-03-31 |
Biogen Idec Inc |
Humanized CRIPTO binding molecules with CDRs from murine B3F6
|
RU2404193C2
(ru)
|
2005-03-25 |
2010-11-20 |
Дженентек, Инк. |
Способ лечения опухоли у субъекта
|
EP1863519B1
(en)
|
2005-03-31 |
2013-09-25 |
The General Hospital Corporation |
Modulating hgf/hgfr activity for treating lymphodema
|
CA2605037C
(en)
|
2005-04-15 |
2015-02-24 |
Genentech, Inc. |
Hgf beta chain variants
|
JP2008545753A
(ja)
*
|
2005-06-02 |
2008-12-18 |
ギャラクシー バイオテック, エルエルシー |
抗体で脳腫瘍を処置する方法
|
TW200732350A
(en)
*
|
2005-10-21 |
2007-09-01 |
Amgen Inc |
Methods for generating monovalent IgG
|
AU2006318580A1
(en)
*
|
2005-11-21 |
2007-05-31 |
Merck Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
DK2463305T3
(en)
|
2006-01-12 |
2016-08-29 |
Alexion Pharma Inc |
Antibodies to OX-2 / CD200 and uses thereof
|
JP5137818B2
(ja)
*
|
2006-03-20 |
2013-02-06 |
生化学工業株式会社 |
関節リウマチの処置剤
|
US8101727B2
(en)
*
|
2006-03-30 |
2012-01-24 |
Novartis Ag |
Compositions and methods of use for antibodies of c-Met
|
AR059922A1
(es)
*
|
2006-04-01 |
2008-05-07 |
Galaxy Biotech Llc |
Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
|
TWI442965B
(zh)
*
|
2006-11-01 |
2014-07-01 |
Biogen Idec Inc |
使用低pH及二價陽離子分離生物巨分子的方法
|
JP2010514692A
(ja)
|
2006-12-20 |
2010-05-06 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
|
EP2014681A1
(en)
*
|
2007-07-12 |
2009-01-14 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
AU2016228280B2
(en)
*
|
2007-07-12 |
2019-02-21 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
AU2014200630B2
(en)
*
|
2007-07-12 |
2016-10-06 |
Pierre Fabre Medicament |
Novel antibodies inhibiting c-met dimerization, and uses thereof
|
KR20100036362A
(ko)
|
2007-07-25 |
2010-04-07 |
알렉시온 파마슈티칼스, 인코포레이티드 |
자가면역 질환 치료 방법 및 조성물
|
EP2197421A1
(en)
*
|
2007-08-31 |
2010-06-23 |
Amgen, Inc |
Solid-state protein formulation
|
ES2750254T3
(es)
*
|
2007-09-27 |
2020-03-25 |
Amgen Inc |
Formulaciones farmacéuticas
|
EP3381445B1
(en)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
CA2716670A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
CA2716851A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Genentech, Inc. |
Combination therapy with c-met and egfr antagonists
|
IL198545A0
(en)
*
|
2008-05-14 |
2011-07-31 |
Metheresis Translational Res Sa |
High affinity binding site of hgfr and methods for identification of antagonists thereof
|
US8455623B2
(en)
*
|
2008-05-21 |
2013-06-04 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
EP2143441A1
(en)
|
2008-07-08 |
2010-01-13 |
Pierre Fabre Medicament |
Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
|
US20100055099A1
(en)
*
|
2008-08-29 |
2010-03-04 |
Ellen Filvaroff |
Diagnostics and Treatments for VEGF-Independent Tumors
|
PA8849001A1
(es)
|
2008-11-21 |
2010-06-28 |
Lilly Co Eli |
Anticuerpos de c-met
|
AR074439A1
(es)
*
|
2008-12-02 |
2011-01-19 |
Pf Medicament |
Anticuerpo anti-cmet (receptor c-met)
|
US8545839B2
(en)
*
|
2008-12-02 |
2013-10-01 |
Pierre Fabre Medicament |
Anti-c-Met antibody
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
WO2010064089A1
(en)
*
|
2008-12-02 |
2010-06-10 |
Pierre Fabre Medicament |
Novel anti-cmet antibody
|
PL3903829T3
(pl)
|
2009-02-13 |
2023-08-14 |
Immunomedics, Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
CN102378768A
(zh)
|
2009-04-07 |
2012-03-14 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-3/抗-c-Met抗体
|
EP2417164A1
(en)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispecific anti-erbb-2/anti-c-met antibodies
|
CA2774260C
(en)
|
2009-09-16 |
2018-10-09 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
AU2010310457B2
(en)
|
2009-10-23 |
2015-07-02 |
Amgen Inc. |
Vial adapter and system
|
KR101671378B1
(ko)
*
|
2009-10-30 |
2016-11-01 |
삼성전자 주식회사 |
c-Met에 특이적으로 결합하는 항체 및 그의 용도
|
KR101748707B1
(ko)
*
|
2009-11-27 |
2017-06-20 |
삼성전자주식회사 |
c-Met에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
|
EP2506881B1
(en)
|
2009-12-02 |
2024-03-06 |
Immunomedics, Inc. |
Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
|
EP3511342B1
(en)
*
|
2010-03-10 |
2024-01-17 |
Genmab A/S |
Monoclonal antibodies against c-met
|
BR112012026766B1
(pt)
|
2010-04-20 |
2021-11-03 |
Genmab A/S |
Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
|
CN103025353A
(zh)
*
|
2010-05-14 |
2013-04-03 |
霍夫曼-拉罗奇有限公司 |
治疗方法
|
SG194370A1
(en)
|
2010-06-07 |
2013-11-29 |
Amgen Inc |
Drug delivery device
|
JP2013532627A
(ja)
|
2010-07-01 |
2013-08-19 |
武田薬品工業株式会社 |
cMET阻害剤とHGFおよび/またはcMETに対する抗体との組み合わせ
|
DK2591099T3
(da)
|
2010-07-09 |
2021-02-15 |
Bioverativ Therapeutics Inc |
Kimære koagulationsfaktorer
|
EP2621483A1
(en)
|
2010-09-27 |
2013-08-07 |
Exelixis, Inc. |
Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
|
WO2012059562A1
(en)
|
2010-11-03 |
2012-05-10 |
Argen-X-Bv |
C-met antibody combinations
|
JP6087148B2
(ja)
|
2010-12-15 |
2017-03-01 |
大学共同利用機関法人情報・システム研究機構 |
タンパク質の生産方法
|
US9480624B2
(en)
|
2011-03-31 |
2016-11-01 |
Amgen Inc. |
Vial adapter and system
|
PT2699293T
(pt)
|
2011-04-20 |
2019-05-21 |
Amgen Inc |
Aparelho de autoinjeção
|
AR086823A1
(es)
|
2011-06-30 |
2014-01-22 |
Genentech Inc |
Formulaciones de anticuerpo anti-c-met, metodos
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
MX2014002289A
(es)
|
2011-08-26 |
2015-03-20 |
Merrimack Pharmaceuticals Inc |
Anticuerpos fc especificos en tandem.
|
WO2013043452A1
(en)
|
2011-09-20 |
2013-03-28 |
Eli Lilly And Company |
Anti-c-met antibodies
|
AU2012322796B2
(en)
|
2011-10-14 |
2017-03-16 |
Amgen Inc. |
Injector and method of assembly
|
US10344050B2
(en)
|
2011-10-27 |
2019-07-09 |
Genmab A/S |
Production of heterodimeric proteins
|
EP2773660A2
(en)
|
2011-11-03 |
2014-09-10 |
Argen-X B.V. |
Chimeric human-camel antigens and their use
|
RU2014124842A
(ru)
|
2011-11-21 |
2015-12-27 |
Дженентек, Инк. |
Очистка анти-с-мет антител
|
EP2785741A1
(en)
|
2011-12-02 |
2014-10-08 |
Cancer Research Technology Limited |
Antibodies against hgf - receptor and uses
|
US8900582B2
(en)
|
2011-12-22 |
2014-12-02 |
Samsung Electronics Co., Ltd. |
Deimmunized anti c-Met humanized antibodies and uses thereof
|
CA2860579A1
(en)
|
2012-01-10 |
2013-07-18 |
Biogen Idec Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CA2877573A1
(en)
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
CN104837502B
(zh)
|
2012-10-12 |
2018-08-10 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其结合物
|
US20150259430A1
(en)
|
2012-11-05 |
2015-09-17 |
Mab Discovery Gmbh |
Method for the production of multispecific antibodies
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
US9695228B2
(en)
|
2012-11-21 |
2017-07-04 |
Janssen Biotech, Inc. |
EGFR and c-Met fibronectin type III domain binding molecules
|
JP2015535464A
(ja)
|
2012-11-21 |
2015-12-14 |
アムジエン・インコーポレーテツド |
薬剤送達装置
|
BR112015013444B1
(pt)
|
2012-12-13 |
2022-11-01 |
Immunomedics, Inc |
Uso de um imunoconjugado
|
ITTO20130012A1
(it)
*
|
2013-01-09 |
2014-07-10 |
Metheresis Translational Res S A |
Nuovi frammenti anticorpali, relative composizioni ed usi
|
BR112015021462A2
(pt)
|
2013-03-06 |
2017-10-10 |
Adimab Llc |
anticorpos biespecíficos anti-c-met tandem fc
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドMedImmune Limited |
ピロロベンゾジアゼピン及びその結合体
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
EP2968760B1
(en)
|
2013-03-15 |
2024-01-03 |
Amgen Inc. |
Drug cassette, autoinjector, and autoinjector system
|
EP2968498A4
(en)
|
2013-03-15 |
2016-09-07 |
Biogen Ma Inc |
PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE
|
TWI639449B
(zh)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
用於注射器之匣盒
|
LT2976117T
(lt)
|
2013-03-22 |
2021-02-25 |
Amgen Inc. |
Purkštuvas ir surinkimo būdas
|
CN105899226B
(zh)
|
2013-10-14 |
2020-05-12 |
詹森生物科技公司 |
半胱氨酸工程化iii型纤连蛋白域结合分子
|
EP3501575B1
(en)
|
2013-10-24 |
2021-12-01 |
Amgen Inc. |
Drug delivery system with temperature-sensitive-control
|
EP3789064A1
(en)
|
2013-10-24 |
2021-03-10 |
Amgen, Inc |
Injector and method of assembly
|
WO2015119906A1
(en)
|
2014-02-05 |
2015-08-13 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
AU2015219495B2
(en)
|
2014-02-21 |
2019-11-21 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
CA2945026C
(en)
|
2014-05-07 |
2023-10-10 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
CA2948003C
(en)
|
2014-06-03 |
2023-06-27 |
Amgen Inc. |
Drug delivery system and method of use
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
US10188746B2
(en)
|
2014-09-10 |
2019-01-29 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
IL250902B
(en)
|
2014-09-16 |
2022-08-01 |
Symphogen As |
Anti-met antibodies and preparations
|
MX2021014323A
(es)
|
2014-10-14 |
2023-02-02 |
Amgen Inc |
Dispositivo de inyección de fármaco con indicadores visuales y audibles.
|
US10799630B2
(en)
|
2014-12-19 |
2020-10-13 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
ES2785311T3
(es)
|
2014-12-19 |
2020-10-06 |
Amgen Inc |
Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
|
EP3954993A1
(en)
|
2015-02-04 |
2022-02-16 |
Bristol-Myers Squibb Company |
Methods of selecting therapeutic molecules
|
EP3253875B1
(en)
|
2015-02-04 |
2020-01-08 |
H. Hoffnabb-La Roche Ag |
Tau antisense oligomers and uses thereof
|
CA2976935C
(en)
|
2015-02-17 |
2020-03-10 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
EP3261690B1
(en)
|
2015-02-27 |
2021-12-15 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
JP6746845B2
(ja)
|
2015-04-22 |
2020-08-26 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
循環trop−2陽性癌細胞の単離、検出、診断及び/または特徴付け
|
EP3313443B9
(en)
|
2015-06-25 |
2023-10-04 |
Immunomedics, Inc. |
Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
EP3316885B1
(en)
|
2015-07-01 |
2021-06-23 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
WO2017160799A1
(en)
|
2016-03-15 |
2017-09-21 |
Amgen Inc. |
Reducing probability of glass breakage in drug delivery devices
|
US11541168B2
(en)
|
2016-04-29 |
2023-01-03 |
Amgen Inc. |
Drug delivery device with messaging label
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
WO2017197222A1
(en)
|
2016-05-13 |
2017-11-16 |
Amgen Inc. |
Vial sleeve assembly
|
EP3458988B1
(en)
|
2016-05-16 |
2023-10-18 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
EP3465124A1
(en)
|
2016-06-03 |
2019-04-10 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
JP2019527540A
(ja)
|
2016-06-21 |
2019-10-03 |
ヤンセン バイオテツク,インコーポレーテツド |
システイン操作フィブロネクチンiii型ドメイン結合分子
|
GB201611123D0
(en)
|
2016-06-27 |
2016-08-10 |
Euremab Srl |
Anti met antibodiesand uses thereof
|
US11285266B2
(en)
|
2016-07-01 |
2022-03-29 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
WO2018081234A1
(en)
|
2016-10-25 |
2018-05-03 |
Amgen Inc. |
On-body injector
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
|
SI3544634T1
(sl)
|
2016-11-23 |
2021-08-31 |
Eli Lilly And Company |
Konjugati zdravila s protitelesom proti met
|
US10626165B2
(en)
|
2016-12-14 |
2020-04-21 |
Janssen Biotech, Inc. |
CD8a-binding fibronectin type III domains
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
JP2020503976A
(ja)
|
2017-01-17 |
2020-02-06 |
アムジエン・インコーポレーテツド |
注入デバイスならびに関連する使用および組立方法
|
JP7280189B2
(ja)
|
2017-02-17 |
2023-05-23 |
アムジエン・インコーポレーテツド |
薬物送達装置用の挿入機構
|
AU2018220538B2
(en)
|
2017-02-17 |
2023-12-14 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
JP2020508803A
(ja)
|
2017-03-06 |
2020-03-26 |
アムジエン・インコーポレーテツド |
作動防止特徴部を備える薬物送達デバイス
|
KR102627069B1
(ko)
|
2017-03-07 |
2024-01-18 |
암겐 인코포레이티드 |
과압에 의한 바늘 삽입
|
JP2020509837A
(ja)
|
2017-03-09 |
2020-04-02 |
アムジエン・インコーポレーテツド |
薬剤送達装置のための挿入機構
|
LT3600491T
(lt)
|
2017-03-28 |
2023-10-10 |
Amgen Inc. |
Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
|
US11590294B2
(en)
|
2017-06-08 |
2023-02-28 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
MX2019014615A
(es)
|
2017-06-08 |
2020-02-07 |
Amgen Inc |
Dispositivo de administracion de farmacos accionado por par de torsion.
|
EP3641857A1
(en)
|
2017-06-22 |
2020-04-29 |
Amgen Inc. |
Device activation impact/shock reduction
|
EP3641861A1
(en)
|
2017-06-23 |
2020-04-29 |
Amgen Inc. |
Electronic drug delivery device comprising a cap activated by a switch assembly
|
JP7408398B2
(ja)
|
2017-07-14 |
2024-01-05 |
アムジエン・インコーポレーテツド |
二重ねじりばねシステムを有する針挿入後退システム
|
IL271173B2
(en)
|
2017-07-21 |
2024-04-01 |
Amgen Inc |
Gas permeable sealing element for drug container and methods of assembly
|
WO2019022950A1
(en)
|
2017-07-25 |
2019-01-31 |
Amgen Inc. |
DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
|
JP2020528296A
(ja)
|
2017-07-25 |
2020-09-24 |
アムジエン・インコーポレーテツド |
ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
|
EP3664863A2
(en)
|
2017-08-09 |
2020-06-17 |
Amgen Inc. |
Hydraulic-pneumatic pressurized chamber drug delivery system
|
EP3668567A1
(en)
|
2017-08-18 |
2020-06-24 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY
|
EP3691717B1
(en)
|
2017-10-04 |
2023-02-08 |
Amgen Inc. |
Flow adapter for drug delivery device
|
EP4257164A3
(en)
|
2017-10-06 |
2024-01-17 |
Amgen Inc. |
Drug delivery device with interlock assembly and related method of assembly
|
MA50348A
(fr)
|
2017-10-09 |
2020-08-19 |
Amgen Inc |
Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
|
WO2019090086A1
(en)
|
2017-11-03 |
2019-05-09 |
Amgen Inc. |
Systems and approaches for sterilizing a drug delivery device
|
EP3706830A1
(en)
|
2017-11-06 |
2020-09-16 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
US20200338271A1
(en)
|
2017-11-06 |
2020-10-29 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
CN111225696B
(zh)
|
2017-11-10 |
2023-07-18 |
安进公司 |
用于药物递送装置的柱塞
|
SG11202003004RA
(en)
|
2017-11-16 |
2020-04-29 |
Amgen Inc |
Door latch mechanism for drug delivery device
|
MX2020005066A
(es)
|
2017-11-16 |
2020-08-20 |
Amgen Inc |
Autoinyector con deteccion de detencion y punto final.
|
IT201800000535A1
(it)
|
2018-01-03 |
2019-07-03 |
|
Procedimenti per la cura del cancro.
|
CN113286616A
(zh)
|
2018-05-23 |
2021-08-20 |
Adc治疗有限公司 |
分子佐剂
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
US20210260279A1
(en)
|
2018-07-24 |
2021-08-26 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
WO2020023444A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
US20210128844A1
(en)
|
2018-07-24 |
2021-05-06 |
Amgen Inc. |
Delivery devices for administering drugs
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
CA3103105A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
AU2019347710A1
(en)
|
2018-09-24 |
2021-02-04 |
Amgen Inc. |
Interventional dosing systems and methods
|
EP3856283A1
(en)
|
2018-09-28 |
2021-08-04 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
WO2020072577A1
(en)
|
2018-10-02 |
2020-04-09 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
MA53818A
(fr)
|
2018-10-05 |
2022-01-12 |
Amgen Inc |
Dispositif d'administration de médicament ayant un indicateur de dose
|
EA202191037A1
(ru)
|
2018-10-15 |
2021-08-05 |
Эмджен Инк. |
Устройство доставки лекарственного средства, имеющее демпферный механизм
|
EP3866889A1
(en)
|
2018-10-15 |
2021-08-25 |
Amgen Inc. |
Platform assembly process for drug delivery device
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
US20220031939A1
(en)
|
2018-11-01 |
2022-02-03 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
MA54048A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
|
AU2020224136A1
(en)
|
2019-02-21 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-MET antibodies and bispecific antigen binding molecules that bind MET
|
AU2020263289A1
(en)
|
2019-04-24 |
2021-09-16 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
JP2022541850A
(ja)
*
|
2019-07-26 |
2022-09-27 |
アンビス メディスンズ,インク. |
肝細胞を産生するための方法および組成物
|
EP4017560A2
(en)
|
2019-08-23 |
2022-06-29 |
Amgen, Inc |
Drug delivery device with configurable needle shield engagement components and related methods
|
CA3146933A1
(en)
|
2019-09-16 |
2021-03-25 |
Marcus KELLY |
Radiolabeled met binding proteins for immuno-pet imaging
|
WO2021076574A2
(en)
|
2019-10-14 |
2021-04-22 |
Aro Biotherapeutics Company |
Fn3 domain-sirna conjugates and uses thereof
|
JP2022551204A
(ja)
|
2019-10-14 |
2022-12-07 |
アロ・バイオセラピューティクス・カンパニー |
Cd71結合フィブロネクチンiii型ドメイン
|
US20230149543A1
(en)
|
2020-04-14 |
2023-05-18 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|
AU2022279223A1
(en)
|
2021-05-21 |
2023-10-19 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
AU2022339667A1
(en)
*
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2024050466A1
(en)
|
2022-09-01 |
2024-03-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating non-small cell lung cancer using mesenchymal epithelial transition factor (met)-targeted agents
|